Learn about the new features in industry’s only in vitro dissolution software for formulation and analytical scientists.
DILIsym® is Quantitative systems toxicology (QST) software for modeling drug-induced liver injury (DILI). Learn about the latest updates in version 8A.
The RENAsym Consortium will unite the world’s leading biopharmaceutical companies within a pre-competitive arena to collaborate, share ideas, and guide the development of a novel QST platform for predicting and understanding drug-induced kidney injury, RENAsym™.
PBPK modeling & simulation package – supporting internal research through regulatory interactions.
To improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services.
Ensuring the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation.
Providing strategic pharmacology and pharmacometric consulting services, PK/PD model development with NONMEM, clinical trial simulations, exposure-response evaluations, dose justification strategies and related data management services.
While our focus for the solutions we provide was initially targeted for pharmaceutical research & development, we have earned a sound reputation in other markets as we develop stronger relationships with regulatory agencies like the U.S. FDA, U.S. EPA, EMA, PMDA, ECHA, and more.
Stay up-to-date with our upcoming conference attendance & presentations, application webinars, and training workshop courses.
Find out how your peers are applying our technology by reviewing journal articles describing various user case studies.